Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
39 hedge funds and large institutions have $20.6M invested in Paratek Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 3 closing their positions.
67% more call options, than puts
Call options by funds: $20K | Put options by funds: $12K
0% more funds holding
Funds holding: 39 → 39 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
13% less capital invested
Capital invested by funds: $23.6M → $20.6M (-$2.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$230K |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$102K |
| 3 |
SG Americas Securities
New York
|
+$70.2K |
| 4 |
Renaissance Technologies
New York
|
+$45.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$945K |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$446K |
| 3 |
Two Sigma Investments
New York
|
-$97.7K |
| 4 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
-$61.3K |
| 5 |
Two Sigma Advisers
New York
|
-$41K |
PRTK Hedge Fund Activity: Q1 2014 in Review
39 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2014, worth a combined $20.6M — down 13% from $23.6M a quarter earlier.
Fund positioning in PRTK was balanced in Q1 2014: 3 funds opened new positions, 3 closed out, 10 added to existing stakes and 10 trimmed.
The largest buyer was Bridgeway Capital Management, adding an estimated $230K. The largest seller was Sabby Management, exiting entirely with an estimated $945K sold.
- 39 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2014, unchanged from Q4 2013.
- Funds reported $20.6M of Paratek Pharmaceuticals, Inc. stock for Q1 2014, down 13% quarter-over-quarter.
- 3 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2014 and 3 closed out, a net change of 0 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2014 was Bridgeway Capital Management, an estimated $230K added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2014 was Sabby Management, an estimated $945K sold.
Based on aggregated 13F filings for Q1 2014.